Biotechnology - Biotechnology, Genito-urinary

Filter

Popular Filters

Athersys disappointed by Phase II MultiStem study results in UC

29-04-2014

US biotech firm Athersys has announced that interim results from the Phase II clinical study of its MultiStem…

AthersysBiotechnologyChronic, moderate-to-severe UCClinical researchGenito-urinaryHealthMedicineRefractory ulcerative colitisResearchUSA

NovaBay Pharmaceuticals: tuning in for a crescendo of data, say analysts

13-05-2013

US biotech firm NovaBay Pharmaceutical's (Nasdaq: NBY) first-quarter 2013 results set the scene for a…

Antibiotics and Infectious diseasesauricloseneBiotechnologyFinancialGenito-urinaryNovaBay PharmaceuticalNVC-422OphthalmicsResearch

AstraZeneca to acquire Ardea Bio for $1.26 billion

23-04-2012

In line with its stated policy of making strategic, rather than mega, acquisitions, Anglo-Swedish drug…

Anti-Arthritics/RheumaticsArdea BiosciencesAstraZenecaBiotechnologyGenito-urinarylesinuradMergers & AcquisitionsPharmaceutical

Company Spotlight

ImmunoGen

ImmunoGen

Back to top